Neurocrine Biosciences Inc
NBIX126.995USD
-1.915-1.49%
Market hours （ET）Quotes delayed by 15 min
12.57BMarket Cap
41.11P/E TTM
More Details of Neurocrine Biosciences Inc Company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
Ticker SymbolNBIX
Company nameNeurocrine Biosciences Inc
IPO dateMay 23, 1996
CEODr. Kyle W. Gano, Ph.D.
Number of employees1800
Security typeOrdinary Share
Fiscal year-endMay 23
Address6027 Edgewood Bend Court
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92130
Phone18586177600
Websitehttps://www.neurocrine.com/
Ticker SymbolNBIX
IPO dateMay 23, 1996
CEODr. Kyle W. Gano, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Kyle W. Gano, Ph.D.
Dr. Kyle W. Gano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
140.11K
+0.14%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Director
Independent Director
120.48K
+1.21%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
40.36K
+7.65%
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Independent Director
Independent Director
34.48K
+9.08%
Mr. Darin M. Lippoldt, J.D.
Mr. Darin M. Lippoldt, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.10K
+8.90%
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.29K
--
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
13.54K
+26.88%
Mr. George J. Morrow
Mr. George J. Morrow
Independent Director
Independent Director
7.07K
+68.33%
Ms. Johanna Mercier
Ms. Johanna Mercier
Independent Director
Independent Director
3.54K
+68.33%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kyle W. Gano, Ph.D.
Dr. Kyle W. Gano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
140.11K
+0.14%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Director
Independent Director
120.48K
+1.21%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
40.36K
+7.65%
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Independent Director
Independent Director
34.48K
+9.08%
Mr. Darin M. Lippoldt, J.D.
Mr. Darin M. Lippoldt, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.10K
+8.90%
Revenue Breakdown
FY2024
FY2023
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
INGREZZA
2.31B
0.00%
Other
17.10M
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
INGREZZA
2.31B
0.00%
Other
17.10M
0.00%
Shareholding Stats
Updated: Thu, May 15
Updated: Thu, May 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.87%
The Vanguard Group, Inc.
9.98%
Dodge & Cox
5.58%
State Street Global Advisors (US)
4.90%
Renaissance Technologies LLC
2.52%
Other
66.15%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.87%
The Vanguard Group, Inc.
9.98%
Dodge & Cox
5.58%
State Street Global Advisors (US)
4.90%
Renaissance Technologies LLC
2.52%
Other
66.15%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.97%
Investment Advisor/Hedge Fund
33.61%
Hedge Fund
11.66%
Pension Fund
2.53%
Research Firm
2.09%
Bank and Trust
1.46%
Individual Investor
1.06%
Private Equity
1.05%
Family Office
0.56%
Other
1.01%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1305
98.03M
98.85%
-6.73M
2025Q1
1337
99.69M
100.72%
-4.46M
2024Q4
1312
98.79M
98.90%
-3.53M
2024Q3
1263
97.40M
96.49%
-4.44M
2024Q2
1241
97.92M
97.33%
-1.65M
2024Q1
1200
97.20M
96.69%
-3.28M
2023Q4
1158
96.37M
98.09%
-3.68M
2023Q3
1123
95.61M
97.90%
-5.53M
2023Q2
1101
95.03M
97.40%
-6.72M
2023Q1
1121
95.04M
97.47%
-5.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
10.78M
10.89%
-179.10K
-1.63%
Mar 31, 2025
The Vanguard Group, Inc.
9.90M
10%
-228.88K
-2.26%
Mar 31, 2025
Dodge & Cox
5.53M
5.59%
+2.52M
+83.48%
Mar 31, 2025
State Street Global Advisors (US)
4.86M
4.91%
-29.02K
-0.59%
Mar 31, 2025
Renaissance Technologies LLC
2.50M
2.53%
+13.30K
+0.53%
Mar 31, 2025
Wellington Management Company, LLP
2.10M
2.12%
+640.56K
+43.95%
Mar 31, 2025
JP Morgan Asset Management
2.03M
2.05%
+985.43K
+94.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.97M
1.99%
+94.69K
+5.05%
Mar 31, 2025
Bellevue Asset Management AG
1.82M
1.84%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
1.49M
1.5%
+627.00K
+72.74%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Tema Neuroscience and Mental Health ETF
4.95%
Simplify Health Care ETF
4.48%
AdvisorShares Psychedelics ETF
4.41%
iShares Neuroscience and Healthcare ETF
4.39%
First Trust NYSE Arca Biotechnology Index Fund
4.35%
VanEck Biotech ETF
2.85%
Invesco Biotechnology & Genome ETF
2.72%
Goldman Sachs Future Health Care Equity ETF
2.52%
SPDR S&P Biotech ETF
2.46%
Alger Russell Innovation ETF
2.21%
View more
Tema Neuroscience and Mental Health ETF
Proportion4.95%
Simplify Health Care ETF
Proportion4.48%
AdvisorShares Psychedelics ETF
Proportion4.41%
iShares Neuroscience and Healthcare ETF
Proportion4.39%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4.35%
VanEck Biotech ETF
Proportion2.85%
Invesco Biotechnology & Genome ETF
Proportion2.72%
Goldman Sachs Future Health Care Equity ETF
Proportion2.52%
SPDR S&P Biotech ETF
Proportion2.46%
Alger Russell Innovation ETF
Proportion2.21%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
